20/20 Biolabs Inc.
AIDX
Rank in Stocks
#31815
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Share Price
$0.2249
Last synced: 2026-11-11
Market Cap
$2.43M
Change (1 day)
14.98%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade 20/20 Biolabs Inc. (AIDX)
Category
Healthcare
EPS for 20/20 Biolabs Inc. (AIDX)
EPS as of June 2026 TTM: $-0.76
According to 20/20 Biolabs Inc.'s latest financial reports, its current EPS (TTM) is $-0.76. At the end of 2025 the company had an EPS of $-0.60, an increase over its 2024 EPS of $-1.16.
EPS history for 20/20 Biolabs Inc. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.76 | 26.67% |
| 2025 | $-0.60 | -48.28% |
| 2024 | $-1.16 | -13.43% |
| 2023 | $-1.34 | -391.30% |
| 2022 | $0.46 | 4.55% |
| 2021 | $0.44 | -202.33% |
| 2020 | $-0.43 | -15.69% |
| 2019 | $-0.51 | 64.52% |
| 2018 | $-0.31 | 14.81% |
| 2017 | $-0.27 | -43.75% |
| 2016 | $-0.48 | 17.07% |
| 2015 | $-0.41 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $30.27 | -4,082.89% |
US
|
|
| $3.19 | -519.66% |
DE
|
|
| $34.71 | -4,667.11% |
US
|
|
| $1.90 | -350.29% |
SA
|
|
| $0.29 | -137.89% |
CN
|
Questions about 20/20 Biolabs Inc.'s earnings per share (EPS)
What is 20/20 Biolabs Inc.'s earnings per share (EPS)?
20/20 Biolabs Inc.'s earnings per share (EPS) over the last twelve months is $-0.76, as of Jun 2026.
What was 20/20 Biolabs Inc.'s earnings per share (EPS) in 2025?
In 2025, 20/20 Biolabs Inc.'s earnings per share (EPS) was $-0.60, compared with $-1.16 in 2024.
How has 20/20 Biolabs Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, 20/20 Biolabs Inc.'s earnings per share (EPS) was highest in 2022 ($0.46) and lowest in 2023 ($-1.34).
How does 20/20 Biolabs Inc.'s earnings per share (EPS) compare with similar companies?
20/20 Biolabs Inc.'s earnings per share (EPS) ($-0.76) is lower than that of all 5 similar companies listed above. The highest among them is Tenet Healthcare Corporation, with $34.71.